Amended: NextEra Energy Q4 Profit Tops View; Lifts Annual Profit Outlook

(Corrects and replaces the earlier story)

NextEra Energy Inc. (NEE) reported its fourth-quarter net income of $1.20 billion or $0.61 per share, compared to a net loss of $5 million or break even per share in the same quarter last year.

On an adjusted basis, quarterly earnings were $814 million or $0.41 per share, compared to $785 million or $0.40 per share in the previous year. Analysts polled by Thomson Reuters expected the company to report earnings of $0.40 per share for the fourth quarter. Analysts' estimates typically exclude special items.

Operating revenues for the fourth quarter increased to $5.05 billion from $4.40 billion last year. Analysts expected revenues of $6.26 billion for the fourth quarter.

NextEra Energy raised its full-year adjusted earnings outlook to $2.75 to $2.85 per share, from the prior outlook of $2.55 to $2.75. Analysts expect annual earnings of $2.74 per share.

For 2023 through 2025, NextEra Energy expects to grow roughly 6% to 8% per year off the expected 2022 adjusted earnings per share.

For 2023, the company now projects adjusted earnings per share to be between $2.93 and $3.08, up from the prior view of $2.77 to $2.97.

Looking ahead, the company anticipates adjusted earnings per share of $3.13 to $3.33 for 2024, and and $3.35 to $3.60 for 2025.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Salt Lake City, Utah-based Creminelli Fine Meats is recalling around 4,207 pounds of ready-to-eat or RTE parmesan salami sticks citing misbranding and an undeclared allergen, the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS announced. The recall involves 2.6-oz. plastic pouches containing "CREMINELLI FINE MEATS salami minis UNCURED ITALIAN SALAMI PARMESAN" with "BES The U.S. Food and Drug Administration is proposing a rule that will broaden the range of nonprescription or over-the counter drugs available to consumers. The rule titled, "Nonprescription Drug Product with an Additional Condition for Nonprescription Use," is intended to increase options for the development of safe and effective nonprescription drugs. The U.S. Food and Drug Administration announced that Australian organic infant formula and baby food producer, Bellamy's Organic, has agreed to send around 696,000 cans of general formula milk to the United States to meet the supply shortage. Under the FDA's enforcement discretion to source more infant formula to the U.S., the available Bellamy's Organic products include about 1.4 million pounds.
Follow RTT